Interventions to chronic prostatitis/Chronic pelvic pain syndrome treatment. Where are we standing and what's next?

Eur J Pharmacol. 2019 Aug 15:857:172429. doi: 10.1016/j.ejphar.2019.172429. Epub 2019 Jun 3.

Abstract

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a frustrating syndrome. The pathogenesis and state of the art treatment of CP/CPPS are not known. A wide variety of therapies including anti-inflammatories, antibiotics, alpha-blockers, neuropathic pain modulators, and 5α-reductase inhibitors are in practice. These treatment strategies focus on alleviating symptoms in specific domains without treating root-cause and therapeutic outcome is far from satisfactory. We review the literature on current pharmacological treatments for CP/CPPS in detail and suggest future perspectives to modify the treatment strategies. We suggest that introducing novel treatment strategies such as gene editing, and Tregs expressing chimeric receptors may improve the treatment outcomes by inducing immune tolerance and controlling expression of pro-inflammatory cytokines.

Keywords: Chronic prostatitis/Chronic pelvic pain syndrome; Diagnosis; Etiology; Future CP/CPPS therapies; Treatment.

Publication types

  • Review

MeSH terms

  • Chronic Disease
  • Gene Editing
  • Humans
  • Male
  • Pelvic Pain / drug therapy
  • Pelvic Pain / genetics
  • Pelvic Pain / therapy*
  • Prostatitis / drug therapy
  • Prostatitis / genetics
  • Prostatitis / therapy*